
    
      A Phase 3, open-label, uncontrolled, multicenter study to evaluate the safety and efficacy of
      long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. Patients who
      meet all entry criteria for this trial apply NPC-12G gel twice a day for 52 weeks or more.
      Approximately 100 eligible patients will be enrolled.
    
  